Posted by Michael Wonder on 19 Nov 2016
Spectrum Pharmaceuticals says FDA rejects its bladder cancer drug
18 November 2016 - Spectrum Pharmaceuticals said on Friday the U.S. FDA had rejected its bladder cancer treatment, apaziquone.
The company said it was considering a new smaller study for the drug, that would replace an ongoing late-stage study, in which patient enrollment has been stopped.
Apaziquone is being developed to treat non-muscle invasive bladder cancer, also known as early bladder cancer, which accounts for about 80 percent of all bladder cancers.
